EUVIMEDEUVIMED entdecken
Crossref

Pharmacology and Analytical Chemistry Profile of Dapagliflozin, Empagliflozin and Saxagliptin

Mahmoud M. Sebaiy

Clinical Research and Clinical Reports · 2023

DOI: 10.31579/2835-8325/021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research and Clinical Reports, 2023. Verfasst von Mahmoud M. Sebaiy.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus is a worldwide disease that requires special and continuous medical care. Many classes of oral hypoglycemic drugs are currently used; however, the treatment strategy depends on the nature of diabetes type, pharmacological properties of the used drugs in addition to the clinical characteristics of the patient. As such, in this literature review, we will shed the light on the pharmacology and analytical chemistry profile of certain oral hypoglycemic drugs specifically Dapagliflozin, Empagliflozin and Saxagliptin that got attention in the last decade. Mode of action and most of up-to-date reported methods that have been developed for determination of these important anti-diabetic drugs in their pure form, combined form with other drugs, combined form with degradation products, and in biological samples are mentioned in detail.

Zitieren

APA

Sebaiy, M. M. (2023). Pharmacology and Analytical Chemistry Profile of Dapagliflozin, Empagliflozin and Saxagliptin. Clinical Research and Clinical Reports. https://doi.org/10.31579/2835-8325/021

Vancouver

Sebaiy MM. Pharmacology and Analytical Chemistry Profile of Dapagliflozin, Empagliflozin and Saxagliptin. Clinical Research and Clinical Reports. 2023. doi:10.31579/2835-8325/021

BibTeX
@article{Sebaiy2023,
  author = {Sebaiy, Mahmoud M.},
  title = {Pharmacology and Analytical Chemistry Profile of Dapagliflozin, Empagliflozin and Saxagliptin},
  journal = {Clinical Research and Clinical Reports},
  year = {2023},
  doi = {10.31579/2835-8325/021}
}
Kostenlos starten →